1. Home
  2. RXRX vs ADMA Comparison

RXRX vs ADMA Comparison

Compare RXRX & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Recursion Pharmaceuticals Inc.

RXRX

Recursion Pharmaceuticals Inc.

HOLD

Current Price

$3.50

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$11.00

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXRX
ADMA
Founded
2013
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.4B
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
RXRX
ADMA
Price
$3.50
$11.00
Analyst Decision
Buy
Strong Buy
Analyst Count
4
4
Target Price
$7.50
$25.67
AVG Volume (30 Days)
10.4M
8.6M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
14.79
N/A
EPS
N/A
0.60
Revenue
$74,681,000.00
$42,219,783.00
Revenue This Year
$12.11
$27.46
Revenue Next Year
$82.52
$22.11
P/E Ratio
N/A
$18.16
Revenue Growth
26.92
43.85
52 Week Low
$2.80
$7.21
52 Week High
$7.18
$25.67

Technical Indicators

Market Signals
Indicator
RXRX
ADMA
Relative Strength Index (RSI) 51.04 46.12
Support Level $2.89 $7.21
Resistance Level $3.99 $16.61
Average True Range (ATR) 0.17 0.48
MACD 0.04 0.35
Stochastic Oscillator 52.41 85.27

Price Performance

Historical Comparison
RXRX
ADMA

About RXRX Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Share on Social Networks: